GTCbio, Washington D.C.
November 7-9, 2007
Marking its 5th anniversary, the Vaccines: All Things Considered conference aims to make the benefits and impact of vaccines better understood and more accepted by all segments of our society. We have assembled an impressive faculty of speakers with representation from industry, academia and the public sector to address a broad range of vaccine related topics structured in the following sessions: 1. New Targets and Technologies for Vaccines 2. Development of New Vaccines for Major Markets 3. New Vaccines for Emerging Markets 4. Vaccine Policy, Regulation, and Funding 5. New Developments in the Influenza Space Plus, attend the pre-conference workshop on November 7th to gain insight on new manufacturing, methods and techniques as well as FDA guidance. Come and join us in beautiful Washington DC on November 8th and 9th to hear about the latest information on the field of vaccines and participate in stimulating discussions on where it is headed. Come earlier or stay later and enjoy the many historic and cultural delights our nation’s capital has to offer; sites such as the Smithsonian museums including the new Air and Space Annex near Dulles Airport, as well as all the other Museums on the Mall (art, Technology, Air and Space, Natural history); the Kennedy center with its multiple stages and venues, the fall colors in the near by chain of mountains and of course the Supreme Court, Capitol Library of Congress and the White House. Please bring notice of this meeting to colleagues that will benefit from attending. Please register early and submit an abstract.
|
|
Invited Speakers:
|
|
David C. Kaslow, M.D. [KEYNOTE] Vice President, Infectious Diseases and Vaccines Franchise, Merck & Co. George Robertson, Ph.D. Senior Program Manager, BARDA, DHHS Daniel Zimmerman, Ph.D. Senior Vice President Research and Development, Cellular Immunology, CEL-SCI Corporation Frank Rapoport, Esq Partner, McKenna, Long, & Aldridge Reiner Laus, M.D. President and Chief Executive Officer, BN ImmunoTherapeutics David Burt, Ph.D. Head of Research, GlaxoSmithKline Biologicals of N. America Brian Underdown Managing Director, MDS Capital Corporation John Clerici, Esq Partner, McKenna, Long & Aldridge Ken Rosenthal, Ph.D. Professor, NEOUCOM Niranjan Kanesa-thasan, MD, MTMH Director, Clinical (Early Development Cluster), Novartis Vaccines Rahul Singhvi CEO, Novavax Stan Erck President & CEO, IOMAI Paul Chaplin Chief Scientific Officer, Bavarian Nordic Brian Livingston, Ph.D. Director, Preclinical Research, Dynavax Angela Shen International Policy Analyst-Vaccine Specialist, National Vaccine Program Office, DHHS Norman Baylor, Ph.D. Director, Office of Vaccines, CBER, FDA Christian Loucq, M.D. Director, MVI, The PATH Malaria Vaccine Initiative Gail Sofer Director, Regulatory Compliance, GE Healthcare Chris Colwell Director of Healthcare Regulatory Affairs, BIO Michael Vajdy Ph.D. Novartis Vaccines Nicholas M. Valiante, Ph.D. Vaccines Research Director/Project Leader, Novartis Vaccines Alan Shaw, Ph.D. President & Chief Executive Officer, VaxInnate Gerald R. Kovacs, Ph.D. Acting Associate Director, BioShield, BARDA, DHHS Clem Lewin, Ph.D., MBA Vice President Marketing, Policy & Strategy, Acambis Hideki Garren, M.D., Ph.D. Co-founder & VP of Research, Bayhill Therpeutics, Inc.
|
|